ThromboGenics NV News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

08.11.17	ThromboGenics Strengthens Leadership Team - Susan Schneider, MD appointed Chief Medical Officer and Vinciane Vangeersdaele appointed Chief Commercial Officer (GlobeNewswire)
20.10.17	ThromboGenics Business Update - Q3 2017 (GlobeNewswire)
09.10.17	ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR (GlobeNewswire)
28.09.17	ThromboGenics NV : ThromboGenics Successfully Introduces New 'Already-Diluted' Formulation of JETREA® (ocriplasmin) in the US (GlobeNewswire)
28.09.17	ThromboGenics NV : ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting (GlobeNewswire)
18.09.17	ThromboGenics NV : ThromboGenics Regains Global Rights to JETREA® (ocriplasmin) (GlobeNewswire)
07.09.17	ThromboGenics Business Update - H1 2017 (GlobeNewswire)
01.09.17	ONCURIOUS NV acquires unique portfolio of next-generation immuno-oncology assets from VIB (GlobeNewswire)
16.08.17	New ThromboGenics' Ocriplasmin Clinical and Health Economic Data Presented at ASRS 2017 Annual Scientific Meeting in Boston (GlobeNewswire)
10.07.17	ThromboGenics and BioInvent Amending Long-standing Monoclonal Antibody Development Agreement (PR Newswire)
10.07.17	ThromboGenics and BioInvent Amending Long-standing Monoclonal Antibody Development Agreement (PR Newswire)
08.06.17	ThromboGenics to Present the Industry Pipeline of DME Treatments at Upcoming European Society of Ophthalmology Congress, Barcelona, Spain (PR Newswire)
08.06.17	ThromboGenics to Present the Industry Pipeline of DME Treatments at Upcoming European Society of Ophthalmology Congress, Barcelona, Spain (PR Newswire)
24.05.17	ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting in Budapest, Hungary (PR Newswire)
24.05.17	ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting in Budapest, Hungary (PR Newswire)
11.05.17	ThromboGenics Business Update - Q1 2017 (PR Newswire)
11.05.17	ThromboGenics Business Update - Q1 2017 (PR Newswire)
02.05.17	New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore (PR Newswire)
02.05.17	New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore (PR Newswire)
20.04.17	ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema (PR Newswire)
20.04.17	ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema (PR Newswire)
16.03.17	ThromboGenics Business Update - FY 2016 (PR Newswire)
16.03.17	ThromboGenics Business Update - FY 2016 (PR Newswire)
10.01.17	ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema (DME) (PR Newswire)
10.01.17	ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema (DME) (PR Newswire)
01.03.16	ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease 18 March in London (GlobeNewswire)
13.01.16	ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial (GlobeNewswire)
07.01.16	Oncurious NV Announces FDA Acceptance of Investigational New Drug (IND) Application for a Phase I/IIa Study with TB-403 for the Treatment of Pediatric Brain Tumors (GlobeNewswire)
18.11.15	ThromboGenics Reports Positive 2 Year Results from the OASIS Study with JETREA® (ocriplasmin) for the treatment of Symptomatic VMA/VMT and Macular Hole (GlobeNewswire)
13.11.15	ThromboGenics Presents Full OASIS JETREA Trial Data Analysis (incl ERG) and Further Real World Clinical Data at Upcoming AAO 2015 in Las Vegas (GlobeNewswire)
12.11.15	ThromboGenics Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase II Study with JETREA® for the Treatment of Non-Proliferative Diabetic Retinopathy (CIRCLE) (GlobeNewswire)
05.11.15	ThromboGenics Business Update - Q3 2015 (GlobeNewswire)
10.09.15	Baron Philippe Vlerick increases shareholding in ThromboGenics NV to 6.4% (GlobeNewswire)
26.08.15	ThromboGenics Business Update H1 2015 (GlobeNewswire)
26.06.15	Oncurious NV Appoints Prof Dr Peter Carmeliet as its Chief Scientific Strategy Advisor (GlobeNewswire)
21.05.15	ThromboGenics Q1 2015 Business Update (GlobeNewswire)
23.04.15	ThromboGenics Starts Evaluating JETREA® for the Treatment of Retinal Vein Occlusion (RVO) (GlobeNewswire)
14.04.15	ThromboGenics and VIB launch New Oncology Company (GlobeNewswire)
24.03.15	OASIS Study Clarification with regard to number of ERM Patients recruited (GlobeNewswire)
24.03.15	ThromboGenics Announces Positive Topline Results from OASIS Study (GlobeNewswire)
16.03.15	ThromboGenics' JETREA® Gains Approval in Brazil (GlobeNewswire)
12.03.15	ThromboGenics Full Year 2014 Business Update (GlobeNewswire)
05.03.15	ThromboGenics Appoints Dr Joseph Markoff as Scientific Advisor (GlobeNewswire)
02.03.15	ThromboGenics Receives Positive CHMP Opinion for Ready Diluted Formulation of JETREA® (GlobeNewswire)
05.02.15	Thrombogenics Awarded €1.1 million IWT Research Grant (GlobeNewswire)
22.01.15	ThromboGenics Appoints Emmanuèle Attout as Independent Non-Executive Director (GlobeNewswire)
07.01.15	ThromboGenics Appoints Dominique Vanfleteren as new Chief Financial Officer (GlobeNewswire)
23.10.13	National Institute for Health and Care Excellence (NICE) in the UK Recommends Reimbursing ThromboGenics' JETREA® for Treatment of a Broad Range of Patients with Vitreomacular Traction (VMT),... (PR Newswire)
23.10.13	National Institute for Health and Care Excellence (NICE) in the UK Recommends Reimbursing ThromboGenics' JETREA® for Treatment of a Broad Range of Patients with Vitreomacular Traction (VMT),... (PR Newswire)
21.10.13	ThromboGenics' JETREA® Nominated for 2013 Prix Galien USA (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Lonza Grp	535.20	0.79 %	K V
Sonova Hldg	306.60	0.66 %	K V
Roche Hldg G	252.30	0.36 %	K V
Novartis	92.18	0.27 %	K V
Alcon	77.78	0.21 %	K V
ABB	49.20	-0.69 %	K V
CieFinRichemont	121.40	-0.78 %	K V
UBS Group	27.54	-0.79 %	K V
Sika	226.40	-0.96 %	K V
Logitech Intl	70.66	-1.83 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu ThromboGenics NV

Aktien Top/Flop

Meistgelesene Nachrichten